Real-world investigation of the use of a mental health chatbot app while waiting for mental health services

Submission date
07/12/2022

Registration date
17/01/2023

Last Edited
22/11/2023

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Mental and Behavioural Disorders

[_] Prospectively registered

[X] Protocol

[_] Statistical analysis plan

[X] Results

[_] Individual participant data

Plain English summary of protocol

Background and study aims
Mental health concerns can have a large impact on individuals, healthcare systems, and the economy. Over a million people are referred to UK mental health services each year, but many have to wait a long time for assessment and treatment and receive limited sessions. This study will examine the impact of a digital health app - called Wysa - on symptoms of depression and anxiety for people waiting for UK mental health services.

Who can participate?
Adults who can speak and understand English and have been referred or have referred themselves to the Improving Access to Psychological Therapies (IAPT) pathway

What does the study involve?
After agreeing to participate, patients complete a set of surveys assessing baseline symptoms of depression, anxiety, and health-related quality of life. All participants will then be randomly assigned to either receive Wysa immediately for 3 months or to wait 3 months to receive Wysa. At the end of the 3 months, all participants will complete the same questionnaires. A small group of participants will also be invited to take part in an interview to discuss their experiences with Wysa.

What are the possible benefits and risks of participating?
Using Wysa has the potential to reduce symptoms of depression and anxiety. Participants assigned to the group that has access to Wysa will receive immediate mental health and well-being support from the app, in addition to the standard treatment they will receive in the IAPT service. This research will also benefit patients in the future.

Potential risks are minimized by providing Wysa as an addition to appointments with IAPT, so all participants will still be assessed and treated in line with current NHS and IAPT guidance. There may be occasions where Wysa doesn't understand what a user is saying or might just keep giving the same answer. This could be frustrating, but we will use this information to help improve Wysa in the future.

All research projects carry some risk that might not be known about before the research project starts, but the team has done everything it can to help make sure these do not happen. The main risk of this research project is that it could increase participants' level of distress - such as if using Wysa is causing frustration and anxiety. Participants can withdraw from the project at any time if they feel it is making their symptoms worse. There is also a risk of the physical impact of increased reliance on mobile phone screen time, which could be mitigated through mobile phone screen access time controls. There is also a risk of storage of potentially identifiable conversations with Wysa, for example, if participants' were to reference their full name or the name of others when interacting with Wysa. There is a procedure which is run on the system to prevent the storage of such information, but should this occur and information cannot be deleted, a notification will be made on the participants' clinical record providing them with the ability to review this information and ask for its removal from Wysa. If Wysa detects language or phrases which have been flagged as indicative of risk of self-harm, suicidality, harm from others or harm to others, Wysa will clarify if it has understood the participant's meaning correctly. If it has, Wysa will trigger the SOS pathway. This pathway can also be manually triggered at any time by clicking on the SOS button on the top right side of the screen and will provide links to local crisis helpline numbers and processes. It will remind participants that Wysa is an AI chatbot and is unable to help during emergencies, but that participants can call these numbers for immediate support.

Where is the study run from?
The study is based out of the Central North West London NHS Trust (UK) and the data analysis is being led by the University of Plymouth (UK)

When is the study starting and how long is it expected to run for?
July 2021 to July 2023

Who is funding the study?
National Institute for Health and Care Research (NIHR) Artificial Intelligence in Health and Care Award (UK)

Who is the main contact?
Prof Edward Meinert (University of Plymouth), edward.meinert@plymouth.ac.uk (UK)
Emma Selby (Wysa), emma@wysa.ai (UK)

Study website
https://communitylivingwell.co.uk/wysa/

Contact information

Type(s)
Principal Investigator

Contact name
Prof Edward Meinert

ORCID ID
http://orcid.org/0000-0003-2484-3347

Contact details

Centre for Health Technology
University of Plymouth
Plymouth
United Kingdom
PL4 6DN
+44 (0)1752 600600
edward.meinert@plymouth.ac.uk

Type(s)
Scientific

Contact name
Prof Edward Meinert

Contact details
Centre for Health Technology
University of Plymouth
Plymouth
United Kingdom
PL4 6DN
+44 (0)1752 600600
edward.meinert@plymouth.ac.uk

Type(s)
Public

Contact name
Miss Emma Selby

Contact details
Wysa
22 Wenlock Road
London
United Kingdom
N1 7GU
None provided
emma@wysa.ai

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
310377

ClinicalTrials.gov number
NCT05533190

Secondary identifying numbers

Study information

Scientific Title
Real-world randomised controlled trial of an artificial intelligence-enabled app as an early intervention and support tool in the mental health referral care pathway

Study objectives
Patients awaiting mental health services who can use an AI-enabled self-help and triage app (Wysa) are more likely to have reduced symptoms of depression and anxiety compared to patients without access.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 25/05/2022, London - Stanmore Research Ethics Committee (2nd Floor, 2 Redman Place, Stratford, London, E20 1JQ, UK; +44 (0)207 104 8387, (0)207 104 8263; stanmore.rec@hra.nhs.uk), ref: 22/PR/0467

Study design
Randomized study

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Home

Study type(s)
Treatment

Participant information sheet
See trial outputs table

Health condition(s) or problem(s) studied
Mental health

Interventions
The study will be a non-blinded randomised controlled trial and mixed-methods evaluation. We are conducting a randomised controlled trial to compare whether Wysa can reduce symptoms of depression and anxiety better than the current standard of care. The mixed-methods evaluation will enable us to gain more in-depth feedback about users' experiences with the Wysa app. The study will last 17 months: 5 months of preparation, 9 months of implementation and follow-up, and 3 months of post-evaluation analysis and preparation for sharing results.
We plan to recruit 480 individuals over 18 years old who are referred, or self-refer, to the

Improving Access to Psychological Therapies (IAPT) service for mental health support. People will be screened for eligibility by a psychology assistant, emailed information about the study, and then called by the assistant to gather informed consent. After consenting, participants will be randomly assigned to the intervention group or a waitlist control group by a computer algorithm.

Participants in the intervention group will be given immediate access to Wysa and participants in the control group will receive access after 3 months. Outcomes will be measured at 3 months post-randomisation in both groups. The researchers evaluating clinical outcomes will be blinded to the participants' groups.

A random subset of participants (stratified based on demographics) will also be invited to participate in an interview about their experience with Wysa. These interviews will last no more than 40-60 minutes and will take place over the phone or via video-calling software.

The study will not alter the current standard of care, as the intervention will be delivered in addition to existing clinical pathways.

Intervention Type
Behavioural

Primary outcome measure
1. Depression severity measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline and 3 months

Secondary outcome measures
1. Anxiety severity measured using the Generalised Anxiety Disorder Assessment (GAD-7) at baseline and 3 months
2. Crisis identification measured using the number of users identified by the app for escalation of care compared to the number of patients in the control group who access accident and emergency or out-of-hours services while waiting for treatment over the 9-month intervention period
3. Uptake rates of the app by participants randomised into the intervention group measured using app download and log in data over the 9-month intervention period
4. Dropout rates of participants who are randomised into the intervention group and start using the app measured using app download and log in data over the 9-month intervention period
5. Frequency and duration of app use measured using app metrics over the 9-month intervention period
6. Qualitative feedback about engagement with the app and its acceptability will be assessed in a subset of participants measured using semi-structured interviews; randomly selected participants will be interviewed once for 40-60 minutes after their use of the Wysa app during the 9-month intervention period
7. Self-reported acceptability measured through the app using automated review questions periodically requested during the general use of the tool over the 9-month intervention period
8. General health state measured using the EuroQol EQ-5D-5L questionnaire at baseline and 3 months
9. Impact of health on everyday life measured using the Short Form 12 (SF-12) health survey at baseline and 3 months
10. Cost-analysis measured using compiled cost data relating to health and social care service use, medication and treatment use, Wysa's implementation, and patients' personal payments or related productivity losses over the 9-month intervention period

Overall study start date

01/07/2021

Completion date

20/07/2023

Eligibility

Key inclusion criteria

1. Willing and able to provide informed consent
2. Aged 18 years or older
3. User is confident in their ability to speak and understand English at a proficient level
4. Own a mobile device capable of supporting Wysa
5. A valid email address
6. Referred or self-referred to proceed through the standard IAPT care pathway

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 480; UK Sample Size: 480

Total final enrolment

76

Key exclusion criteria

1. Patients ineligible for the standard IAPT care pathway
2. Patients with previous and current known major mental illness such as Schizophrenia, severe depression, any co-morbid neurological or neuro-psychiatric condition such as epilepsy
3. Patients with current psychosis or a history of psychotic symptoms within the last 6 months
4. Patients with suicidal ideation
5. Patients scoring > 15 points on PHQ 9
6. Patients scoring > GAD-7
7. Patients with significant cognitive disorders
8. Patients with noted neurodevelopmental conditions such as autism or ADHD
9. Patients previously diagnosed with a personality disorder
10. Patients who been under the care of CMHT or a specialised mental health services in the last 2 years
11. Patients who failed IAPT previously
12. Patients with referrals for specialist presentations of pre-existing, diagnosed conditions requiring a specialised assessment beyond the standard clinical pathway

13. Incapable of self-consent
14. In a dependent/unequal relationship with the research or care teams or any PPI representatives

Date of first enrolment
16/12/2022

Date of final enrolment
24/04/2023

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Central and North West London NHS Foundation Trust
Trust Headquarters
350 Euston Road
Regents PLACE
London
United Kingdom
NW1 3AX

Sponsor information

Organisation
University of Plymouth

Sponsor details
Level 2
Marine Building
Drake Circus
Plymouth
England
United Kingdom
PL4 8AA
+44 (0)1752588959
plymouth.sponsor@plymouth.ac.uk

Sponsor type
Hospital/treatment centre

Website

https://www.plymouth.ac.uk/

ROR
https://ror.org/008n7pv89

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Planned publication in a high-impact and peer reviewed journal. The protocol is planned to be published in BMJ Open by Spring 2023.

Intention to publish date
31/08/2024

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository (the University of Plymouth archive servers). Anonymised data will be made available on request from Professor Edward Meinert (edward.meinert@plymouth.ac.uk) subject to a data use agreement between the Contractor and the third party requesting the data. If any participant does not consent to the sharing of their anonymised data for other research purposes, that data will be removed from the dataset before it is made available to other researchers, and the file will be noted accordingly to indicate that it is a subset of the initial dataset.

IPD sharing plan summary

Stored in non-publicly available repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 1.1		17/01/2023	No	Yes
Protocol (preprint)	version 1.1	29/09/2022	17/01/2023	No	No
HRA research summary			28/06/2023	No	No
Basic results			22/11/2023	No	No